Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole

Inclusion Criteria: * All subjects to be of sub-Saharan African origins with both parents of sub-Saharan African origins too, * Male subjects with a body mass index (BMI) calculated as weight in kg/(height in m2) from 18 to 28 kg/m2 at screening, * Able to communicate well with the Investigator and research staff and to comply with the requirements of the entire study, * Provision of written informed consent to participate as shown by a signature on the volunteer consent form, * Light smokers (less than 5 cigarettes per day) or subjects who are non-smokers. * Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not clinically significant by the principal Investigator. * Registered with the French Social Security in agreement with the French law on biomedical experimentation. Exclusion Criteria: * Who on direct questioning and physical examination have evidence of any clinically significant acute or chronic disease, including known or suspected HIV, HBV or HCV infection, * Who previously received fexinidazole, * With any clinically significant abnormality following review of pre-study laboratory tests(ASAT, ALAT and ALP must be within normal ranges), vital signs, full physical examination and ECG, * Who are within the exclusion period defined in the National Register for Healthy Volunteers of the French Ministry of Health, * Who forfeit their freedom by administrative or legal award or who were under guardianship, * Unwilling to give their informed…